May 24, 2021

Fintech Zoom – Novavax Stock – INSIGHT Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way

Novavax Stock- INSIGHT Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way

Top executives at U.S. pharmaceutical company Novavax Inc (NVAX.O) aren’t waiting to see how well their COVID-19 vaccine works before they reap the financial rewards.

Chief Executive Stanley Erck and three of his top lieutenants have sold roughly $46 million of company stock since the start of last year, according to a Reuters review of securities filings, capitalizing on a near 3,000% rally in Novavax shares fueled by investors betting on the success of the shot under development.

Tweet
Email
Share